Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside
Travere Therapeutics, Inc.
Travere Therapeutics Inc. (TVTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 8,876,000 | $131,364,800 | +1% | 2.27% |
| 2. | 45,689,000 | $43,701,816 | +10% | 0.03% | |
| 3. | Adage Capital Management Phill Gross And Robert Atchinson | 2,784,000 | $41,203,200 | +28% | 0.07% |
| 4. | 41,667,000 | $39,748,380 | 0.6% | ||
| 5. | Renaissance Technologies Jim Simons | 2,495,114 | $36,927,687 | -8% | 0.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.85 | 5,000 | $89,250.00 | 245,556 | 2017-06-14 | Filing | |
| $15.31 | 5,000 | $76,564.50 | 52,000 | 2016-03-04 | Filing | |
| $8.60 | 15,000 | $129,049.50 | 35,000 | 2014-11-25 | Filing | |
| $8.38 | 6,100 | $51,118.00 | 129,165 | 2014-11-21 | Filing | |
| $8.50 | 8,700 | $73,950.00 | 371,756 | 2014-11-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $30.12 | 27,128 | $817,073.66 | 419,173 | 2025-10-29 | Filing | |
| $30.38 | 92,872 | $2,821,358.49 | 419,173 | 2025-10-28 | Filing | |
| $30.00 | 2,662 | $79,860.00 | 124,662 | 2025-10-28 | Filing | |
| $25.00 | 10,000 | $250,000.00 | 89,878 | 2025-09-22 | Filing | |
| $19.71 | 119 | $2,345.49 | 92,083 | 2025-09-04 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,599,668 | $38,232,065 | 0.5% | |
| 2. | 194,854 | $4,657,011 | 0% | |
| 3. | 93,355 | $2,231,185 | 0% | |
| 4. | 84,097 | $2,009,906 | 0.11% | |
| 5. | 68,232 | $1,630,745 | 0.11% |
News See All
Citi Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA Catalysts
Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best small cap stocks with biggest upside potential.
9 Best Small Cap Stocks with Biggest Upside Potential
On August 14, Jonathan Krinsky of BTIG, joined 'Closing Bell' on CNBC to discuss whether the recent rally in small cap stocks is sustainable.
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Travere Therapeutics Second Quarter 2025 Financial Results Conference Call. Today's call is being recorded.
Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX)
Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.
13 Best Pharma Stocks to Buy According to Wall Street Analysts
On June 24, Jared Holz, Mizuho's healthcare strategist, appeared on CNBC's 'Fast Money' to talk about competition in the obesity drug space.
Travere Therapeutics Kicks Off "Play It Forward" Campaign for FSGS Awareness
Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best biotech stocks to invest in now.
13 Best Biotech Stocks To Invest In Now
In 2023, the global biotechnology market size was estimated at $1.55 trillion.
HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs
Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 10 Best Growth Stocks Under $100 to Buy Now.
10 Best Growth Stocks Under $100 to Buy Now
Even if asked by a layman where they would want to invest, the answer would be straight: growth stocks.
Hedge Fund Resource Center Billionaire Hedge Funds
